Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and Vigonvita Shanghai Co. Ltd. have described NMDA and serotonin receptor antagonists reported to be useful for the treatment of neurological disorders.

Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Suzhou Vigonvita Life Sciences Co. Ltd. have described NMDA receptor antagonists and/or monoamine transporter inhibitors reported to be useful for the treatment of neurological disorders.

Researchers from Huiankai (Xiamen) Pharmaceutical Technology Co. Ltd., Quanzhou Haichuang Pharmaceutical Technology Co. Ltd. and Suzhou Grandkol Pharm Technology Co. Ltd. have discovered new compounds.

Researchers at Bexson Biomedical Inc. and Saint Joseph’s University have synthesized NMDA receptor antagonists reported to be useful for the treatment of neurological and psychiatric disorders.

Scientists at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and The Xinjiang Technical Institute of Physics & Chemistry of the Chinese Academy of Sciences have disclosed NMDA receptor antagonists reported to be useful for the treatment of neurological disorders.